| Walter Ernst Galicich, MD | |
|
800 E 28th St, 305 Piper Bldg., Minneapolis, MN 55407-3723 | |
| (612) 871-7278 | |
| (612) 879-7189 |
| Full Name | Walter Ernst Galicich |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 32 Years |
| Location | 800 E 28th St, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457369241 | NPI | - | NPPES |
| 38689 | Other | MN | LICENSE |
| 649542700 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 38689 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hennepin County Medical Center 1 | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hennepin Healthcare System Inc | 4789684861 | 794 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Psychogenic polydipsia is associated with significantly reduced left insula volume in patients with schizophrenia, researchers report.
Researchers at the University of Glasgow and the Manchester Metropolitan University in the U.K. report that adults with intellectual disabilities have a higher risk of being infected with SARS-CoV2. They are also more likely to develop worse outcomes once infected.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
› Verified 8 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Psychogenic polydipsia is associated with significantly reduced left insula volume in patients with schizophrenia, researchers report.
Researchers at the University of Glasgow and the Manchester Metropolitan University in the U.K. report that adults with intellectual disabilities have a higher risk of being infected with SARS-CoV2. They are also more likely to develop worse outcomes once infected.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
› Verified 8 days ago
| Entity Name | Hennepin Healthcare System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138136 PECOS PAC ID: 4789684861 Enrollment ID: O20070207000467 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Psychogenic polydipsia is associated with significantly reduced left insula volume in patients with schizophrenia, researchers report.
Researchers at the University of Glasgow and the Manchester Metropolitan University in the U.K. report that adults with intellectual disabilities have a higher risk of being infected with SARS-CoV2. They are also more likely to develop worse outcomes once infected.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Walter Ernst Galicich, MD 800 E 28th St, 305 Piper Bldg., Minneapolis, MN 55407-3723 Ph: (612) 871-7278 | Walter Ernst Galicich, MD 800 E 28th St, 305 Piper Bldg., Minneapolis, MN 55407-3723 Ph: (612) 871-7278 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Psychogenic polydipsia is associated with significantly reduced left insula volume in patients with schizophrenia, researchers report.
Researchers at the University of Glasgow and the Manchester Metropolitan University in the U.K. report that adults with intellectual disabilities have a higher risk of being infected with SARS-CoV2. They are also more likely to develop worse outcomes once infected.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
› Verified 8 days ago
Dr. Robert Allen Mcgovern Iii, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Kendall Mceachron, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 420 Delaware St Se, Mayo Mail Code 195, Minneapolis, MN 55455 Phone: 612-625-6483 | |
Gaylan L Rockswold, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 701 Park Ave, P5, Minneapolis, MN 55415 Phone: 612-873-2810 | |
Stanley A Skinner, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 E 28th St, Minneapolis, MN 55407 Phone: 612-863-3200 Fax: 612-863-2837 | |
Dr. Zhiyi Sha, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 420 Delaware Street S.e., Mmc 295, Minneapolis, MN 55455 Phone: 612-624-9025 Fax: 612-624-8111 | |
Kristen E Jones, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 161-267-2742 Fax: 612-676-8992 | |
John Charles Mullan, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 800 E 28th St, 305 Piper Bldg., Minneapolis, MN 55407 Phone: 612-871-7278 Fax: 612-879-7189 |